Compare AstraZeneca plc (AZN) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? AstraZeneca plc trades at $158.63 (market cap $248.14B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.01 (market cap $78.85B). The key difference: AstraZeneca plc is far larger — about 3.1× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| AZN | MDLZ | |
|---|---|---|
Market Cap | $248.14B | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $64.99 |
52-Week Low | $147.06 | $51.51 |
Enterprise Value | $275.41B | $99.19B |
Dividend Yield | 2.01% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Mondelez International (MDLZ) trades at $61.71, up 0.28% on the day, reflecting steady momentum after a series of earnings beats. The stock exhibits a bullish technical trend, supported by strong moving averages. Fundamentally, the company reported Q2 2026 EPS of $0.73, exceeding estimates, and raised its organic sales outlook for 2026. Revenue growth is solid, though net income margin compression from 2023 peaks remains a watch point. Analyst sentiment is overwhelmingly positive, with a consensus price target of $70.50 implying significant upside.
The outlook for MDLZ is favorable, driven by pricing power, volume growth in emerging markets, and a robust brand portfolio. Key opportunities include market share gains and consistent dividend payments. Primary risks involve exposure to international economic volatility, inflationary cost pressures, and intense competition in the snack food industry. The stock presents a compelling case for growth-oriented investors seeking stability in consumer staples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
